Chinese medicine pharmacoeconomics research standard introduced

Pharmacoeconomics evaluation will set off a new chapter in the development of the Chinese medicine industry. Recently, in Tianjin, organized by the Department of Science and Technology of the State Administration of Traditional Chinese Medicine, the "Introduction to the Seminar on Empirical Pharmaceutical Economics and the Development of Traditional Chinese Medicine Industry and the Standardization of Traditional Chinese Medicines and Pharmaceutical Economics" was held in Tianjin. The “Drug Medicine Economics Research Criteria” (Draft), jointly prepared by the Center for Pharmacy, Regulations and Translational Medicine, University College of Pharmacy, Evidence-based Pharmacoeconomics Evaluation Research Center, and Bonove Pharmacoeconomics Research Center, was agreed with leaders and experts. sure.

Pharmacoeconomics is the specific application of economic principles and methods in the field of medicine. In western developed countries, pharmacoeconomics has developed for nearly 30 years, and is widely accepted and applied by drug manufacturers. However, the practical application of pharmacoeconomics in China is still at a very early stage, especially in the field of Chinese medicine, whether it is normative guidelines. Theory or strength research is basically a blank.

Tianjin University School of Pharmacy, Research Center for Drug Administration and Translational Medicine, Evidence-Based Evaluation and Research Center for Pharmaceutical Economics, and Bonovo Pharmaceutical Economics Research Center, with the support of the leaders of relevant management departments, refer to the pharmacoeconomics guidelines and research of various countries in the world. Progress, after a series of long-term, extensive and in-depth studies on the issues and challenges faced by traditional Chinese medicine in the evaluation of pharmacoeconomics, the work was jointly carried out to formulate the “Standard for the Study of Chinese Medicine Pharmacoeconomics” (draft), with a view to better The pricing policy of Chinese medicine products provides evidence-based medicine and evidence-based economics of medicine, guiding enterprises to optimize and upgrade their products, helping enterprises to obtain support through policies such as research and pricing, and promoting the cultivation of large varieties and the development of the Chinese medicine industry. After two passes, five drafts were completed and a complete research specification was finally released. At the meeting, the contents of the draft were highly appreciated by the participating leaders and experts, and pointed out the direction for the next step.

Experts and enterprises jointly discuss the development of traditional Chinese medicine pharmacoeconomics by the Pharmaceutical and Regulatory Statistic and Translational Medicine Research Center of Tianjin University School of Pharmacy, the Evidence-Based Evaluation and Research Center for Pharmacoeconomics, the Bonov Pharmaceutical Economics Research Center and the World Federation of Chinese Medicine (TCMGA) ) Co-host. The meeting invited the Deputy Director Li Daning of the State Administration of Traditional Chinese Medicine and the leaders of the People's Insurance Department, the National Development and Reform Commission, and other management departments, as well as Zhang Beli, Sun He, Sun Lihua, Wu Jing, Song Ruilin, Wu Shengxian, and Wang Wei, and a number of clinical evaluations and drug economics. Experts of academic evaluation attended the meeting, including a group of Chinese medicine companies such as Shenzhen Sanjiu, Zhejiang Kangenbei, Shandong Dong'e Ejiao and others. Participating leaders and experts conducted in-depth discussions on how pharmacoeconomics fits with the characteristics of traditional Chinese medicine, how to standardize the development, promote the development of the Chinese medicine industry, and promote the details of medical insurance reimbursement and pricing decisions. Experts at the meeting believe that the future focus of work will need to be based on this research and standardize the specific varieties of pharmaceutical companies through case studies, so that the standard of research and landing, but also promote the implementation of norms. Wang Hao, director of the Bonowi Research Center for Pharmacoeconomics, said that he will use his own advantages to provide positive case studies and data support.

Deputy Director-General Li Daning of the State Administration of Traditional Chinese Medicine stated that: The economics of Chinese medicine should be used as a decision-making auxiliary tool. It is determined in the formulation of pharmaceutical policies, optimization of drug resources allocation, selection of prevention and treatment options, pricing of medicines, national essential drug list, and drug reimbursement catalog. And management, drug expense compensation level determination, clinical rational drug guidance, new drug research and development strategy and other aspects play an important reference and guidance. The State proposes that enterprises should make greater efforts to conduct pharmacoeconomics research on the basis of this research standard. The State Administration of Traditional Chinese Medicine will set up special projects to support enterprises in this regard.

Academician Zhang Boli believes: From the national point of view, we must consider strengthening the study of pharmacoeconomics. It is of great significance to formulate the principles and norms of the pharmacoeconomics of traditional Chinese medicines and study the pricing strategies of traditional Chinese medicines.

Professor Sun He, director of the Pharmaceutical Administration Law and Translational Medicine Research Institute of Tianjin University's School of Pharmacy, said that he would actively promote the establishment of the Chinese medicine pharmacoeconomics evaluation research standard and further promote discipline development and industrial development.

The Bonowie Research Center for Pharmacoeconomics participated in the formulation of the "Standard for the Study of Pharmacoeconomics of Traditional Chinese Medicine" (draft). It is reported that the center has completed a comparative study of the pharmacoeconomics guidelines of 33 countries and regions around the world, and has conducted a number of clinical evaluations of traditional Chinese medicine drug economics. Dr. Wang Wei, director of the Center, believes that in the current medical environment, given that most chronic diseases are treated with complex interventions, treatment options and treatment pathways increasingly refer to various treatment guidelines at home and abroad, making design of traditional Chinese medicine drug economics evaluation And the implementation is faced with many practical challenges. It needs to consider more factors and the design is more complex. At the design stage, we must fully research and evaluate the impact of a large number of clinical practical problems and the differences in medical and health policies in different regions. The promulgation of the "Standard for the Study of Pharmacoeconomics of Chinese Materia Medica" (draft) provides a good reference for future research.

The participating companies all stated that under the guidance of this research standard, with the support of the government, they are willing to vigorously promote the pharmacoeconomics research of their listed products in order to obtain long-term and rapid development of the products.